CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice

International Journal of Cancer. Journal International Du Cancer
Mohamed H ZakiMohit Trikha

Abstract

IL-6 is a multifunctional cytokine implicated in several cancers. IL-6 is a growth factor for certain tumors and contributes to drug resistance, cachexia and bone resorption. Cachexia is characterized by progressive weight loss and depletion of host reserves of adipose tissue and skeletal muscle. We have developed CNTO 328 (cCLB8), a human-mouse chimeric MAb to IL-6 (K(d) approx. 10(-12) M) that inhibits IL-6 function. A phase I study with CNTO 328 in multiple myeloma patients demonstrated that the antibody was safe and had a circulating half-life of approximately 17 days. Since IL-6 is implicated in cachexia, we hypothesized that CNTO 328 could inhibit tumor-induced cachexia. We used 2 human tumor-induced cachexia models in nude mice. In the first model, human melanoma cells were inoculated in female nude mice. Control treated animals lost 19% (+/-7.7%) body weight from day 0 to day 31, whereas CNTO 328 (10 mg/kg)-treated animals lost only 1.5% (+/-1.3%) body weight from day 0 to day 31 (p = 0.023). In the second cachexia model, human prostate tumor cells were injected into male nude mice. By day 29, control treated animals lost 6% (+/-3.5%) body weight, whereas CNTO 328 (10 mg/kg)-treated animals gained 7% (+/-4%) body weight...Continue Reading

References

May 1, 1992·The Journal of Clinical Investigation·G StrassmannC O Jacob
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P MatthysA Billiau
Jun 1, 1989·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·B A SherryL L Moldawer
Aug 15, 2000·European Journal of Immunology·S MaurayM A Duchosal
Jan 12, 2002·Nature Medicine·Ville WalleniusJohn-Olov Jansson
Apr 9, 2002·Current Oncology Reports·Fade Aziz Mahmoud, Nilo I Rivera
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Hidekuni InaderaKouji Matsushima
Sep 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Masahiko HayashiKanki Komiyama
Nov 5, 2002·Nature Reviews. Cancer·Michael J Tisdale

❮ Previous
Next ❯

Citations

Jun 5, 2012·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jennifer E AdairPamela S Becker
Aug 21, 2008·Pflügers Archiv : European journal of physiology·Kristen A BaltgalvisJames A Carson
Sep 2, 2009·The Proceedings of the Nutrition Society·Chen Bing, Paul Trayhurn
Dec 5, 2012·Nature Reviews. Clinical Oncology·Kenneth FearonVickie Baracos
Apr 25, 2006·Journal of Palliative Medicine·Egidio Del FabbroEduardo Bruera
Sep 28, 2010·Exercise and Sport Sciences Reviews·James A Carson, Kristen A Baltgalvis
Dec 7, 2007·The Journal of Clinical Investigation·Zachary T Schafer, Joan S Brugge
Jan 17, 2012·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Xia YangYu-Zhang Wu
Jun 30, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Robert A Femia, Richert E Goyette
Oct 29, 2009·Expert Opinion on Emerging Drugs·Kate T Murphy, Gordon S Lynch
Aug 19, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Pengwei ZhuangHongyan Li
Feb 24, 2016·Oncogenesis·P E Porporato
Apr 23, 2013·Journal of Pain and Symptom Management·Haruhiko HirataAtsushi Kumanogoh
Aug 13, 2011·European Journal of Pharmacology·Josep M ArgilésFrancisco J López-Soriano
Mar 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tasnim Ara, Yves A Declerck
Apr 20, 2005·Journal of Cellular Biochemistry·Zoran CuligAlfred Hobisch
Mar 28, 2008·Immunological Reviews·Xiao-yun LiuEllen S Vitetta
Feb 5, 2008·British Journal of Pharmacology·P Fischer, D Hilfiker-Kleiner
Apr 8, 2015·British Journal of Clinical Pharmacology·Shalini ChaturvediKate Sasser
Aug 18, 2005·The International Journal of Biochemistry & Cell Biology·Josep M ArgilésFrancisco J López-Soriano
Jul 27, 2005·Nutrition·Josep M ArgilésFrancisco J López-Soriano
May 10, 2005·The International Journal of Biochemistry & Cell Biology·Josep M ArgilésFrancisco J López-Soriano
Jun 27, 2015·The Journal of Endocrinology·Maria Carolina S MendesJosé B C Carvalheira
Jun 23, 2016·SpringerPlus·José E BelizárioEdouard Vannier
Jul 8, 2008·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Layka A AsbaghCag Cal
Apr 12, 2008·Current Opinion in Clinical Nutrition and Metabolic Care·Chen Bing, Paul Trayhurn
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Jun 27, 2018·Journal of Neuroendocrinology·Toru YokoyamaYasuhito Uezono
Dec 7, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kristen A BaltgalvisJames A Carson
Dec 19, 2013·American Journal of Physiology. Endocrinology and Metabolism·Kiyoshi TerawakiYasuhito Uezono
Dec 12, 2019·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Helene Nissrine Daou
Feb 23, 2020·Critical Care Nursing Quarterly·Amanda M RiveraMegan E Barra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.